Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CFD | P00746 | 16/20 | 1.00 |
| ▸ | HTR1A | P08908 | 1/20 | 0.54 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.54 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.54 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16680486 | 1.00 | CFD (1.00) | CFDHTR1AADRA2CADRA1AKCNH2 | |
| SCHEMBL16689336 | 0.89 | CFD (1.00) | CFD | |
| SCHEMBL16680619 | 0.89 | CFD (1.00) | CFDHTR1AADRA2CADRA1AKCNH2 | |
| SCHEMBL16680351 | 0.89 | CFD (1.00) | CFD | |
| SCHEMBL16680621 | 0.89 | CFD (1.00) | CFDHTR1AADRA2CADRA1AKCNH2 | |
| SCHEMBL16689333 | 0.87 | CFD (1.00) | CFD | |
| SCHEMBL17697872 | 0.87 | CFD (1.00) | CFD | |
| SCHEMBL16689340 | 0.80 | HTR1A (0.67) | CFDHTR1AADRA2CADRA1AKCNH2 | |
| SCHEMBL16689341 | 0.79 | CFD (0.64) | CFDHTR1AADRA2CADRA1AKCNH2 | |
| SCHEMBL16689334 | 0.79 | CFD (1.00) | CFD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2864322-B1 | COMPLEMENT PATHWAY MODULATORS AND USES THEREOF | NOVARTIS AG (CH) | 2016-04-27 | — | — | EP | claimed |
| US-9452990-B2 | Complement pathway modulators and uses thereof | NOVARTIS AG (CH) | 2016-09-27 | — | — | US | disclosed |
| EP-2864322-B1 | COMPLEMENT PATHWAY MODULATORS AND USES THEREOF | NOVARTIS AG (CH) | 2016-04-27 | — | — | EP | disclosed |
| US-20150126492-A1 | Complement Pathway Modulators and Uses Thereof | NOVARTIS AG (CH) | 2015-05-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150126492-A1 | Complement Pathway Modulators and Uses Thereof | CFB, CFH, TFPI | CFD 4/4885HTR1A 2356/4885ADRA2C 3202/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.